Altimmune to Participate in Upcoming Investor Conferences

GlobeNewswire

May 27

GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in the following upcoming investor conferences:

2026 Jefferies Global Healthcare Conference
Thursday, June 4, 2026
Fireside chat at 12:50 p.m. ET
New York, NY

Goldman Sachs 47^th Annual Global Healthcare Conference
Wednesday, June 10, 2026
Fireside chat at 8:00 a.m. ET
Miami Beach, FL

A webcast of the fireside chats will be available via the Events section of the Altimmune website.

About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead investigational candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on X

Investor Contact:
Luis Sanay, CFA
Vice President, Investor Relations
ir@altimmune.com

Media Contact:
Real Chemistry
altimmune@realchemistry.com

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2638883386"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2638883386\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2638883386?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-27 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2638883386","market":"hk","top_or_hot":-1,"title":"Altimmune to Participate in Upcoming Investor Conferences","media":"GlobeNewswire","content":"<html><body><p>GAITHERSBURG, Md., May  27, 2026  (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/ALT\">Altimmune, Inc.</a> (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in the following upcoming investor conferences:</p> <ul type=\"disc\"><li><strong>2026 Jefferies Global Healthcare Conference<br/></strong>Thursday, June 4, 2026<br/>Fireside chat at 12:50 p.m. ET<br/>New York, NY<br/></li></ul> <ul type=\"disc\"><li><strong>Goldman Sachs 47</strong><sup><strong>th</strong></sup><strong> Annual Global Healthcare Conference </strong><br/>Wednesday, June 10, 2026<br/>Fireside chat at 8:00 a.m. ET<br/>Miami Beach, FL<br/></li></ul> <p>A webcast of the fireside chats will be available via the Events section of the Altimmune website.</p> <p><strong>About Altimmune</strong><br/>Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead investigational candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.</p> <p><strong>Follow @Altimmune, Inc. on </strong><strong>LinkedIn</strong><br/><strong>Follow @AltimmuneInc on </strong><strong>X</strong></p> <p><strong>Investor Contact:</strong><br/>Luis Sanay, CFA<br/>Vice President, Investor Relations<br/>ir@altimmune.com</p> <p><strong>Media Contact:</strong><br/>Real Chemistry<br/>altimmune@realchemistry.com</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/N2Y4NjlmOGItNDNkZC00NDJlLWJiMDEtNDU1ODliY2Y3NWM0LTEwMjIyNDktMjAyNi0wNS0yNy1lbg==/tiny/Altimmune-Inc.png\"/></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Altimmune to Participate in Upcoming Investor Conferences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAltimmune to Participate in Upcoming Investor Conferences\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1016364462\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">GlobeNewswire </p>\n<p class=\"h-time\">2026-05-27 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>GAITHERSBURG, Md., May  27, 2026  (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/ALT\">Altimmune, Inc.</a> (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in the following upcoming investor conferences:</p> <ul type=\"disc\"><li><strong>2026 Jefferies Global Healthcare Conference<br/></strong>Thursday, June 4, 2026<br/>Fireside chat at 12:50 p.m. ET<br/>New York, NY<br/></li></ul> <ul type=\"disc\"><li><strong>Goldman Sachs 47</strong><sup><strong>th</strong></sup><strong> Annual Global Healthcare Conference </strong><br/>Wednesday, June 10, 2026<br/>Fireside chat at 8:00 a.m. ET<br/>Miami Beach, FL<br/></li></ul> <p>A webcast of the fireside chats will be available via the Events section of the Altimmune website.</p> <p><strong>About Altimmune</strong><br/>Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead investigational candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.</p> <p><strong>Follow @Altimmune, Inc. on </strong><strong>LinkedIn</strong><br/><strong>Follow @AltimmuneInc on </strong><strong>X</strong></p> <p><strong>Investor Contact:</strong><br/>Luis Sanay, CFA<br/>Vice President, Investor Relations<br/>ir@altimmune.com</p> <p><strong>Media Contact:</strong><br/>Real Chemistry<br/>altimmune@realchemistry.com</p> <br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml.globenewswire.com/media/N2Y4NjlmOGItNDNkZC00NDJlLWJiMDEtNDU1ODliY2Y3NWM0LTEwMjIyNDktMjAyNi0wNS0yNy1lbg==/tiny/Altimmune-Inc.png\"/></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALD","symbol_name":"联合资本","start_time":0,"source_url":"https://www.globenewswire.com/news-release/2026/05/27/3301939/0/en/Altimmune-to-Participate-in-Upcoming-Investor-Conferences.html","article_id":"2638883386","we_media_id":"1016364462","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2638883386","pubTimestamp":1779885000,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"GlobeNewswire","introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the world’s largest and most trusted newswires.","home_visible":1,"id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"summary":"GAITHERSBURG, Md., May  27, 2026   -- Altimmune, Inc. , a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in the following upcoming investor conferences: 2026 Jefferies Global Healthcare ConferenceThursday, June 4, 2026Fireside chat at 12:50 p.m. ETNew York, NY Goldman Sachs 47th Annual Global Healthcare Conference Wednesday, June 10, 2026Fireside chat at 8:00 a.m. ETMiami Beach, FL A webcast of the fireside chats will be available via the Events section of the Altimmune website. About AltimmuneAltimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead investigational candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis , alcohol use disorder  and","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALD":"联合资本"},"translate_title":"Altimmune将参加即将举行的投资者会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALD":1},"content_text":"GAITHERSBURG, Md., May  27, 2026  (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in the following upcoming investor conferences: 2026 Jefferies Global Healthcare ConferenceThursday, June 4, 2026Fireside chat at 12:50 p.m. ETNew York, NY Goldman Sachs 47th Annual Global Healthcare Conference Wednesday, June 10, 2026Fireside chat at 8:00 a.m. ETMiami Beach, FL A webcast of the fireside chats will be available via the Events section of the Altimmune website. About AltimmuneAltimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead investigational candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com. Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on X Investor Contact:Luis Sanay, CFAVice President, Investor Relationsir@altimmune.com Media Contact:Real Chemistryaltimmune@realchemistry.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}